Social Behavior
Lykos Faces Significant Setbacks as FDA Rejects MDMA Therapy and Three Studies Are Retracted Due to Unethical Conduct
Lykos Therapeutics, MDMA therapy, FDA rejection, study retractions, unethical conduct, PTSD treatment, psychedelic research
Aldeyra’s Reproxalap Demonstrates Efficacy in Reducing Eye Discomfort in New Phase 3 Study
Aldeyra Therapeutics, Reproxalap, Phase 3 Study, Eye Discomfort, Dry Eye Disease, FDA Rejection
Novo Nordisk Faces Setback in IRA Litigation, Vows to Appeal
Novo Nordisk, IRA lawsuit, Medicare price negotiations, legal setback, appeal
IRA Drug Price Reductions Unlikely to Harm Biotech Innovation, Studies Suggest
Inflation Reduction Act, IRA, drug price negotiations, biotech innovation, Medicare, pharmaceutical industry
Biosecure Lawmakers Target China Studies in New Regulatory Push
Biosecure Act, China studies, clinical trials, biopharma, U.S.-China relations, drug production, national security, pharmaceutical supply chain
WuXi AppTec Faces Revenue Decline Amid Looming BIOSECURE Act Threat
WuXi AppTec, BIOSECURE Act, Revenue Decline, Biotechnology, US-China Relations
NICE Rejects AstraZeneca’s Enhertu for Breast Cancer Treatment Due to Pricing Concerns
NICE, AstraZeneca, Enhertu, Breast Cancer, Pricing, Rejection
Viking Therapeutics Accelerates Obesity Drug Development to Phase 3 Trials
Viking Therapeutics, Obesity Drug, Phase 3 Trials, GLP-1/GIP Receptor Agonist, VK2735, Weight Loss, Market Competition
Novartis Partners with Dren Bio in $3 Billion Deal for Targeted Myeloid Engagers
Novartis, Dren Bio, Myeloid Engagers, Biotech, Pharmaceutical, Alliance, $3 Billion Deal
The Best Practice Organization: Key to Success in Today’s Biopharma Industry
Biopharma Industry, Best Practice Organization, Success Factors, Operational Excellence, Business Development Strategy, Talent Strategy, Medical Affairs, Commercial Field Teams, Generative AI, Integrated Teams, Strategic Workforce Planning, Leadership, Culture, Team Dynamics, Talent Experience